Resort at Squaw Creek Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2016
Here are the related meetings in 2020:
HIV Pathogenesis and Cure (X6)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
HIV Persistence: Pathogenesis and Eradication (X7)
Organizer(s) David M. Margolis, Satya Dandekar and Susana T. Valente
March 20—24, 2016
Resort at Squaw Creek • Olympic Valley, CA USA
Discounted Abstract Deadline: Nov 19, 2015
Abstract Deadline: Dec 17, 2015
Scholarship Deadline: Nov 19, 2015
Discounted Registration Deadline: Jan 21, 2016
Sponsored by Gilead Sciences, Inc., Merck & Co., Inc. and Sangamo BioSciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Joint Meeting:
HIV Vaccines (X8)
Summary of Meeting:
Despite the clinical success of antiretroviral therapy (ART), every day there are more people newly infected with HIV than those initiating ART. The complexities of dispensing lifelong ART for HIV-infected individuals make it imperative to develop strategies for HIV eradication, or at least to strictly control the virus without daily therapy. The clearance of a retroviral infection is a herculean task and requires unraveling the mechanisms of viral persistence and host immune interactions. Further, ART does not appear to completely mitigate the impact of HIV infection on human health, and a better understanding of the overt and subtle immune pathologies induced by HIV infection is needed. Recent studies of early therapeutic interventions and HIV-resistant cellular therapies have provided new insights into the development of HIV eradication strategies. The meeting will focus on all aspects of HIV persistence and eradication that include: (1) The understanding of persistent HIV infection; (2) Innate defenses against retroviral infection; (3) The interplay of the host inflammatory response and HIV pathogenesis; and (4) Novel concepts for viral eradication. Special attention will be paid to progress in the development of model systems to study latent infection as well as strategies to eradicate it. Emphasis will be placed on new, unpublished findings that will highlight novel insights and creative strategies to develop effective control and eradication of HIV infection.
View Scholarships/Awards
Despite the clinical success of antiretroviral therapy (ART), every day there are more people newly infected with HIV than those initiating ART. The complexities of dispensing lifelong ART for HIV-infected individuals make it imperative to develop strategies for HIV eradication, or at least to strictly control the virus without daily therapy. The clearance of a retroviral infection is a herculean task and requires unraveling the mechanisms of viral persistence and host immune interactions. Further, ART does not appear to completely mitigate the impact of HIV infection on human health, and a better understanding of the overt and subtle immune pathologies induced by HIV infection is needed. Recent studies of early therapeutic interventions and HIV-resistant cellular therapies have provided new insights into the development of HIV eradication strategies. The meeting will focus on all aspects of HIV persistence and eradication that include: (1) The understanding of persistent HIV infection; (2) Innate defenses against retroviral infection; (3) The interplay of the host inflammatory response and HIV pathogenesis; and (4) Novel concepts for viral eradication. Special attention will be paid to progress in the development of model systems to study latent infection as well as strategies to eradicate it. Emphasis will be placed on new, unpublished findings that will highlight novel insights and creative strategies to develop effective control and eradication of HIV infection.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, March 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 25 in order to fully experience the meeting.
SUNDAY, MARCH 20
MONDAY, MARCH 21
TUESDAY, MARCH 22
WEDNESDAY, MARCH 23
THURSDAY, MARCH 24
FRIDAY, MARCH 25
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 25 in order to fully experience the meeting.
SUNDAY, MARCH 20
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address (Joint)
*
David M. Margolis,
University of North Carolina at Chapel Hill, USA
*
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
Anthony S. Fauci,
NIAID, National Institutes of Health, USA
Recorded Presentation: Ending the HIV/AIDS Pandemic: Follow the Science
Recorded Presentation: Ending the HIV/AIDS Pandemic: Follow the Science
09:00—11:30
Acute HIV Infection and Initial Transmission Events (Joint)
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
*
Nilu Goonetilleke,
University of North Carolina at Chapel Hill, USA
George M. Shaw,
University of Pennsylvania, USA
Novel SHIV Design to Recapitulate HIV-1 Transmission, Persistence and Pathogenesis and as a Guide for Vaccine and Cure Research
Novel SHIV Design to Recapitulate HIV-1 Transmission, Persistence and Pathogenesis and as a Guide for Vaccine and Cure Research
Joseph Eron,
University of North Carolina School of Medicine, USA
Acute HIV Infection: Antiretroviral Therapy and Persistence
Acute HIV Infection: Antiretroviral Therapy and Persistence
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois, Switzerland
Novel Therapeutic Interventions in the Targeting of the HIV Cell Reservoir
Novel Therapeutic Interventions in the Targeting of the HIV Cell Reservoir
Zachary S. Ende,
Centers for Disease Control and Prevention, USA
Short Talk: Heterosexual Transmission of Subtype C HIV-1 Does Not Require Increased Replicative Capacity or Interferon Resistance
Short Talk: Heterosexual Transmission of Subtype C HIV-1 Does Not Require Increased Replicative Capacity or Interferon Resistance
Shilpa Iyer,
University of Pennsylvania, USA
Short Talk: Mucosal Transmission of HIV-1 Selects for Variants with Enhanced Infectivity, Replication Fitness and Interferon Resistance
Short Talk: Mucosal Transmission of HIV-1 Selects for Variants with Enhanced Infectivity, Replication Fitness and Interferon Resistance
11:45—12:45
DAIDS Programmatic Agendas, Recent Review Policy Updates, and Grantsmanship Advice (Joint)
The workshop will consist of four presentations and a question and answer period at the end. Presentation topics: 1. The Persistence and Cure Agenda; 2. HIV Vaccine Initiatives; 3. Overview of Recent Policy Updates on Rigor and Reproducibly; and 4. Tips for Writing NIH Career (K) and Investigator Initiated (R01/R21) Grant Applications.
14:30—16:30
Workshop 1: Requirements for bnAb Induction
*
Pamela J. Bjorkman,
California Institute of Technology, USA
Matthew D. Gray,
Fred Hutchinson Cancer Research Center, USA
Self-assembling HIV Envelope Nanoparticles Increase Antibody Binding, Membrane Dynamics and B-cell Activation
Self-assembling HIV Envelope Nanoparticles Increase Antibody Binding, Membrane Dynamics and B-cell Activation
Christina Guzzo,
NIAID, National Institutes of Health, USA
Critical Role of V2 Sulfotyrosines in Stabilizing the HIV-1 Envelope Trimer in Its Closed, Antibody-Protected Conformation
Critical Role of V2 Sulfotyrosines in Stabilizing the HIV-1 Envelope Trimer in Its Closed, Antibody-Protected Conformation
Colin Havenar-Daughton,
La Jolla Institute for Immunology, USA
Virtual Immunization with eOD-GT8: Probing the Human Naive B Cell Repertoire to a Candidate HIV Vaccine Immunogen
Virtual Immunization with eOD-GT8: Probing the Human Naive B Cell Repertoire to a Candidate HIV Vaccine Immunogen
Cassandra Simonich,
Fred Hutchinson Cancer Research Center, USA
An Infant bNAb with Low Somatic Hypermutation Contributes to Polyclonal Breadth
An Infant bNAb with Low Somatic Hypermutation Contributes to Polyclonal Breadth
Lorena S. Ver,
IAVI, International Aids Vaccine Initiative, USA
Characterization of Neutralizing Antibody Responses to the N332 Site of Vulnerability on HIV Env in IAVI Protocol C Cohort
Characterization of Neutralizing Antibody Responses to the N332 Site of Vulnerability on HIV Env in IAVI Protocol C Cohort
Amelia Escolano,
Rockefeller University, USA
Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Human Ig Knock-in Mice
Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Human Ig Knock-in Mice
Daniela Fera,
Swarthmore College, USA
Structural Analysis of an HIV-1 Broadly Neutralizing B-Cell Lineage Targeting the Env N332 Glycan
Structural Analysis of an HIV-1 Broadly Neutralizing B-Cell Lineage Targeting the Env N332 Glycan
17:00—19:15
Mechanisms of Persistent Infection
*
Steven G. Deeks,
University of California, San Francisco, USA
Jonathan Karn,
Case Western Reserve University, USA
Epigenetic Control of HIV Latency
Epigenetic Control of HIV Latency
Melanie M. Ott,
Gladstone Institutes, USA
Epigenetic Regulation of HIV Latency
Epigenetic Regulation of HIV Latency
Susana T. Valente,
Scripps Florida, USA
Eradication without Reactivation
Eradication without Reactivation
Andrew P. Rice,
Baylor College of Medicine, USA
Regulation of P-TEFb and HIV Latency
Regulation of P-TEFb and HIV Latency
17:00—19:15
Immunologic Correlates of Sterilizing Immunity
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
*
Mark Connors,
NIAID, National Institutes of Health, USA
Merlin L. Robb,
Walter Reed Army Institute of Research, USA
Optimizing Quality and Durability of Immune Responses: Insights from RV 144 Follow-up Studies
Optimizing Quality and Durability of Immune Responses: Insights from RV 144 Follow-up Studies
Genoveffa Franchini,
NCI, National Institutes of Health, USA
Activated RAS in PBMCs and Extracellular Vesicle, Mucosal Envelope Antibody to V2, and Innate Lymphoid Cells are Associated with Vaccine-Mediated Reduced Risk of SIVmac251 Acquisition
Activated RAS in PBMCs and Extracellular Vesicle, Mucosal Envelope Antibody to V2, and Innate Lymphoid Cells are Associated with Vaccine-Mediated Reduced Risk of SIVmac251 Acquisition
Georgia D. Tomaras,
Duke University Medical Center, USA
HIV-1 Vaccine Humoral Immunity, Immune Correlates and Mechanistic Insights
HIV-1 Vaccine Humoral Immunity, Immune Correlates and Mechanistic Insights
Genevieve Fouda,
Duke University Medical Center, USA
Short Talk: HIV Exposed Infants Vaccinated with a rgp120/MF59 Vaccine have Higher Magnitude anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine
Short Talk: HIV Exposed Infants Vaccinated with a rgp120/MF59 Vaccine have Higher Magnitude anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine
Thomas Musich,
1Armed Forces Research Institute of Medical Sciences, Thailand
Short Talk: Vaccine-Induced Effects on Neutrophils in Rhesus Macaques
Short Talk: Vaccine-Induced Effects on Neutrophils in Rhesus Macaques
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Reservoirs and Persistence I
*
Susana T. Valente,
Scripps Florida, USA
Janice E. Clements,
Johns Hopkins University, USA
Tissue Reservoirs of CD4+T Cells and Macrophages in ART Suppressed SIV-Infected Macaques
Tissue Reservoirs of CD4+T Cells and Macrophages in ART Suppressed SIV-Infected Macaques
Satya Dandekar,
University of California, Davis, USA
Early Establishment of HIV Reservoirs
Early Establishment of HIV Reservoirs
John M. Coffin,
Tufts University, USA
Mechanism of HIV Persistence despite Suppressive Antiretroviral Therapy
Mechanism of HIV Persistence despite Suppressive Antiretroviral Therapy
J. Victor Garcia-Martinez,
University of North Carolina at Chapel Hill, USA
In vivo Analysis of HIV Persistence
In vivo Analysis of HIV Persistence
Sara Ferrando-Martinez,
NIAID, National Institutes of Health, USA
Short Talk: Immune Activation Drives Accumulation of Follicular CTL during Chronic HIV/SIV Infection
Short Talk: Immune Activation Drives Accumulation of Follicular CTL during Chronic HIV/SIV Infection
Binhua Ling,
Tulane National Primate Research Center, USA
Short Talk: Gut Viral Reservoirs in SIV-Infected Long-Term Nonprogressing Chinese Rhesus Macaques on Antiretroviral Therapy
Short Talk: Gut Viral Reservoirs in SIV-Infected Long-Term Nonprogressing Chinese Rhesus Macaques on Antiretroviral Therapy
08:00—11:30
Epitopes, Structures and Ontogeny of Broadly Neutralizing Antibodies
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
*
Rogier W. Sanders,
University of Amsterdam and Weill Cornell Medical College, Netherlands
Pamela J. Bjorkman,
California Institute of Technology, USA
Structure-Based Design of Improved Antibodies Against HIV
Structure-Based Design of Improved Antibodies Against HIV
Sasha Murrell,
The Scripps Research Institute, USA
Short Talk: Crystal Structures of Two Related Broadly Neutralizing Antibodies against the N332 Supersite in HIV Env
Short Talk: Crystal Structures of Two Related Broadly Neutralizing Antibodies against the N332 Supersite in HIV Env
Marit van Gils,
Amsterdam UMC, Netherlands
Short Talk: Broadly Neutralizing Antibodies from an Elite Neutralizer Target a Novel Site at the gp120-gp41 Interface
Short Talk: Broadly Neutralizing Antibodies from an Elite Neutralizer Target a Novel Site at the gp120-gp41 Interface
Dennis R. Burton,
The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Guide HIV Vaccine Design
Broadly Neutralizing Antibodies to Guide HIV Vaccine Design
Jinal Nomathemba Bhiman,
The Scripps Research Institute, USA
Viral Variants that Initiate and Drive Maturation of Broadly Neutralizing Antibodies
Viral Variants that Initiate and Drive Maturation of Broadly Neutralizing Antibodies
William Schief,
International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Epitope-Focused HIV Vaccine Design
Epitope-Focused HIV Vaccine Design
Christina Yacoob,
Fred Hutchinson Cancer Research Center, USA
Short Talk: Selective Allelic Expansion of HIV-1 Immunized Rhesus Macaques Based on Different Antigenic Properties of Env Immunogens
Short Talk: Selective Allelic Expansion of HIV-1 Immunized Rhesus Macaques Based on Different Antigenic Properties of Env Immunogens
13:00—14:30
Hands-On Computer Session on Los Alamos Sequence Database
Shared computers will be supplied for the first 60 attendees. Interested participants may sign up for the meeting on a first-come, first-serve basis. If attendance is over 60 people you will be asked to bring your own computer.
14:30—16:30
Workshop 1: Challenges of Persistent HIV Infection
*
Romas Geleziunas,
Gilead Sciences, Inc., USA
Kirston M. Barton,
University of Sydney, Australia
HIV-1 in the Blood and Intestine Contribute to Viremia During Treatment Interruption
HIV-1 in the Blood and Intestine Contribute to Viremia During Treatment Interruption
Ya-Chi Ho,
Yale School of Medicine, USA
Activation of Novel Splice Donor Sites Allows Production of tat and rev Transcripts in Defective Patient-Derived HIV-1 Proviruses
Activation of Novel Splice Donor Sites Allows Production of tat and rev Transcripts in Defective Patient-Derived HIV-1 Proviruses
Lillian B. Cohn,
Chan Zuckerberg Biohub, USA
HIV DNA Integration Site Selection in Productive Infection
HIV DNA Integration Site Selection in Productive Infection
Allison Thomas,
George Washington University, USA
After Long-Term ART, T-cell Responses Targeting Early HIV Proteins Uniquely Correlate with Infected Cell Frequencies
After Long-Term ART, T-cell Responses Targeting Early HIV Proteins Uniquely Correlate with Infected Cell Frequencies
Luca Micci,
Emory University, YNPRC, USA
Determinants of Viral Control following ART-interruption in SIV-infected Rhesus Macaques
Determinants of Viral Control following ART-interruption in SIV-infected Rhesus Macaques
James L. Riley,
University of Pennsylvania, USA
Engineering Chimeric Antigen Receptors for Durable Control over HIV-1 Replication
Engineering Chimeric Antigen Receptors for Durable Control over HIV-1 Replication
Maud Mavigner,
Emory University, USA
Reducing HIV Persistence by Targeting Stem Cell Properties of Memory CD4+ T-cells
Reducing HIV Persistence by Targeting Stem Cell Properties of Memory CD4+ T-cells
Angela Wahl,
University of North Carolina at Chapel Hill, USA
CD4+ Tissue-Resident Memory T Cells are an Important Reservoir for HIV Persistence
CD4+ Tissue-Resident Memory T Cells are an Important Reservoir for HIV Persistence
17:00—19:00
Auxillary Genes and Host Restriction Factors
*
J. Victor Garcia-Martinez,
University of North Carolina at Chapel Hill, USA
Alan N. Engelman,
Dana-Farber Cancer Institute, USA
CPSF6 Regulates HIV-1 Integration into Active Chromatin
CPSF6 Regulates HIV-1 Integration into Active Chromatin
Stephen P. Goff,
Columbia University, USA
Retroviral Silencing: Transcriptional and Post-Transcriptional Regulation
Retroviral Silencing: Transcriptional and Post-Transcriptional Regulation
Michael Emerman,
Fred Hutchinson Cancer Research Center, USA
Evolution of Host Antiviral Restriction Factors
Evolution of Host Antiviral Restriction Factors
Richard Apps,
NCI, National institutes of Health, USA
Short Talk: HIV-1 Immune Evasion by Downregulation of HLA-C
Short Talk: HIV-1 Immune Evasion by Downregulation of HLA-C
17:00—19:15
Vaccine Concepts I
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
David C. Montefiori,
Duke University Medical Center, USA
Standardized Assessments of HIV Vaccine-Elicited Neutralizing Antibodies
Standardized Assessments of HIV Vaccine-Elicited Neutralizing Antibodies
*
Mario Roederer,
NIAID, National Institutes of Health, USA
The SIV Model to Evaluate Antibody-Based Intervention
The SIV Model to Evaluate Antibody-Based Intervention
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
Using Neutralization Resistance/Sensitivity Signatures to Inform Vaccine Design
Using Neutralization Resistance/Sensitivity Signatures to Inform Vaccine Design
Javier Guenaga,
IAVI Neutralizing Antibody Center at TSRI, USA
Short Talk: Display of the HIV-1 Env MPER in the Context of a Well-ordered Soluble Uncleaved (NFL) Trimer
Short Talk: Display of the HIV-1 Env MPER in the Context of a Well-ordered Soluble Uncleaved (NFL) Trimer
James Mark Binley,
San Diego Biomedical Research Institute, USA
Short Talk: Eliciting Tier 2 anti-HIV-1 NAbs using Native, Membrane Trimers
Short Talk: Eliciting Tier 2 anti-HIV-1 NAbs using Native, Membrane Trimers
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Antiviral Host Response and Inflammation
*
Satya Dandekar,
University of California, Davis, USA
Nicolas Chomont,
Université de Montréal, Canada
Immune Checkpoint Molecules and HIV Persistence during ART
Immune Checkpoint Molecules and HIV Persistence during ART
Alberto Bosque,
George Washington University, USA
Short Talk: Targeting Pathogen Recognition Receptors to Reactivate Latent HIV-1
Short Talk: Targeting Pathogen Recognition Receptors to Reactivate Latent HIV-1
Ivona Pandrea,
University of Pittsburgh, USA
Nonhuman Primate Studies with Relevance for Cure Research
Nonhuman Primate Studies with Relevance for Cure Research
David Favre,
GlaxoSmithKline, USA
Immune Modulation as a Strategy to Clear Persistent Infection
Immune Modulation as a Strategy to Clear Persistent Infection
Heinrich Gottlinger,
University of Massachusetts Medical School, USA
Short Talk: SERINC3 and SERINC5 Synergistically Inhibit HIV-1 Infectivity and are Antagonized by Nef
Short Talk: SERINC3 and SERINC5 Synergistically Inhibit HIV-1 Infectivity and are Antagonized by Nef
Catherine A. Blish,
Stanford University School of Medicine, USA
Short Talk: NK Cell Response
Short Talk: NK Cell Response
08:00—11:15
Pathways Leading to Long-Term Protective Immunity Against HIV-1
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
*
Jay A. Berzofsky,
NCI, National Institutes of Health, USA
Bali Pulendran,
Stanford University School of Medicine, USA
Signaling Mechanisms
Signaling Mechanisms
W. Ripley Ballou,
GlaxoSmithKline Vaccines, USA
Inducing Long-Term Protection with Vaccines
Inducing Long-Term Protection with Vaccines
Richard A. Koup,
NIAID, National Institutes of Health, USA
T Cell Help
T Cell Help
Maria Blasi,
Duke University School of Medicine, USA
Use of Integrase Defective Lentiviral Vectors Expressing HIV-Envs to Induce Durable Immune Responses
Use of Integrase Defective Lentiviral Vectors Expressing HIV-Envs to Induce Durable Immune Responses
Jinghe Huang,
NIAID, National Institutes of Health, USA
Short Talk: Intranasal Replication Competent Adenovirus Type 4-Influenza-H5 (Ad4-H5-Vtn) Vaccine Induces Durable Neutralizing Antibody Responses in Humans
Short Talk: Intranasal Replication Competent Adenovirus Type 4-Influenza-H5 (Ad4-H5-Vtn) Vaccine Induces Durable Neutralizing Antibody Responses in Humans
Konstantin Virnik,
Food and Drug Administration, USA
Short Talk: Expression of HIV and SIV Env Proteins in a Highly Immunogenic Rubella Vaccine Platform
Short Talk: Expression of HIV and SIV Env Proteins in a Highly Immunogenic Rubella Vaccine Platform
13:00—14:30
Hands-On Computer Session on Los Alamos Immunology Database
Shared computers will be supplied for the first 60 attendees. Interested participants may sign up for the meeting on a first-come, first-serve basis. If attendance is over 60 people you will be asked to bring your own computer.
14:30—16:30
Workshop 2: New Technologies and Approaches
*
Karl Salzwedel,
NIAID, National Institutes of Health, USA
Collin Kieffer,
University of Illinois at Urbana-Champaign, USA
Longitudinal Imaging of Early HIV infection in Humanized Mice with Parallel 3D Immunofluorescence and Electron Microscopy
Longitudinal Imaging of Early HIV infection in Humanized Mice with Parallel 3D Immunofluorescence and Electron Microscopy
Bonnie J. Howell,
Merck & Co., Inc., USA
Ultrasensitive Detection of Viral p24 following Reactivation of Latent HIV
Ultrasensitive Detection of Viral p24 following Reactivation of Latent HIV
Tram N.Q. Pham,
Institut de Recherches Cliniques de Montreal, Canada
Enhancing Tethering of HIV Virions by BST2/Tetherin Augments the Susceptibility of Productively and Latently Infected T Cells to ADCC Mediated by Broadly Neutralizing Anti-HIV Antibodies
Enhancing Tethering of HIV Virions by BST2/Tetherin Augments the Susceptibility of Productively and Latently Infected T Cells to ADCC Mediated by Broadly Neutralizing Anti-HIV Antibodies
Yik Lim Kok,
University Hospital Zurich, Switzerland
A Novel HIV-1-Based Vector that Reproduces Features of Productive and Latent HIV-1 Infections
A Novel HIV-1-Based Vector that Reproduces Features of Productive and Latent HIV-1 Infections
Julia Sung,
University of North Carolina, USA
HIV specific Ex vivo Expanded T Cell (HXTC) Therapy to Target the Latent Reservoir
HIV specific Ex vivo Expanded T Cell (HXTC) Therapy to Target the Latent Reservoir
Kenneth M. Law,
Icahn School of Medicine at Mount Sinai, USA
Cell-to-cell HIV-1 Transmission Promotes Multicopy Micro-Compartmentalized Infection in Humanized Mice
Cell-to-cell HIV-1 Transmission Promotes Multicopy Micro-Compartmentalized Infection in Humanized Mice
Lydie Trautmann,
US Military HIV Research Program, USA
Differentiation of Effector CD8 T Cells Toward Short Lived Cells Lacking Memory Potential During Acute HIV Infection
Differentiation of Effector CD8 T Cells Toward Short Lived Cells Lacking Memory Potential During Acute HIV Infection
Sarah DiNapoli,
NIAID, National Institutes of Health, USA
Lymphoid Tissue-Resident Myeloid Cells Contain Replication-Competent Virus that is Genetically Similar to Virus from CD4+ T Cells in ARV-Naïve Asian Macaques
Lymphoid Tissue-Resident Myeloid Cells Contain Replication-Competent Virus that is Genetically Similar to Virus from CD4+ T Cells in ARV-Naïve Asian Macaques
17:00—19:00
Cure Studies in Models and Man
*
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
Daria J. Hazuda,
Merck Research Laboratories, USA
HIV Latency Drug Discovery: Optimizing Drugs to Induce Latent HIV Expression
HIV Latency Drug Discovery: Optimizing Drugs to Induce Latent HIV Expression
John W. Mellors,
University of Pittsburgh School of Medicine, USA
Biomarkers of HIV Persistence and Response to Therapeutic Interventions
Biomarkers of HIV Persistence and Response to Therapeutic Interventions
Jerome A. Zack,
University of California, Los Angeles, USA
Synthetic PKC Modulators as HIV Latency Reversing Agents
Synthetic PKC Modulators as HIV Latency Reversing Agents
Lucy Dorrell,
University of Oxford, UK
Short Talk: Elimination of HIV-1 Reservoir Cells from Antiretroviral Therapy-Suppressed Subjects by Engineered Immune-Mobilising Dual Affinity T cell Receptors
Short Talk: Elimination of HIV-1 Reservoir Cells from Antiretroviral Therapy-Suppressed Subjects by Engineered Immune-Mobilising Dual Affinity T cell Receptors
17:00—19:15
Vaccine Concepts II
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
*
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
John P. Moore,
Weill Medical College of Cornell University, USA
How to Make and Use Multiple Native-Like SOSIP Trimers for Vaccine and Structural Studies
How to Make and Use Multiple Native-Like SOSIP Trimers for Vaccine and Structural Studies
Barton F. Haynes,
Duke University Medical Center, USA
B Cell Lineage Immunogen Design Approach to Elicit HIV Broadly Neutralizing Antibodies
B Cell Lineage Immunogen Design Approach to Elicit HIV Broadly Neutralizing Antibodies
Peter D. Kwong,
NIAID, National Institutes of Health, USA
Structure-Based Immunogen Design
Structure-Based Immunogen Design
Marzena Pazgier,
Uniformed Services University of the Health Sciences, USA
Short Talk: Paring down HIV-1 Env: Design and Structure of an Independent Inner Domain of gp120 Stably Expressing the A32 ADCC Epitope Sub-region
Short Talk: Paring down HIV-1 Env: Design and Structure of an Independent Inner Domain of gp120 Stably Expressing the A32 ADCC Epitope Sub-region
Talar Tokatlian,
Massachusetts Institute of Technology, USA
Short Talk: Design and Characterization of gp140 Envelope Trimer-Coupled Liposomes for an HIV Vaccine
Short Talk: Design and Characterization of gp140 Envelope Trimer-Coupled Liposomes for an HIV Vaccine
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—08:45
Keynote Address (Joint)
*
David C. Montefiori,
Duke University Medical Center, USA
John R. Mascola,
NIAID, National Institutes of Health, USA
Active and Passive Antibody-Based Immunity to HIV-1
Active and Passive Antibody-Based Immunity to HIV-1
08:45—11:45
Immunotherapy (Joint)
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.
*
Michael Seaman,
Beth Israel Deaconess Medical Center-Harvard Medical School, USA
David D. Ho,
Aaron Diamond AIDS Research Center, USA
Bispecific Antibodies
Bispecific Antibodies
Michael Farzan,
The Scripps Research Institute, USA
AAV-Expressed eCD4-Ig as an Alternative HIV-1 Vaccine
AAV-Expressed eCD4-Ig as an Alternative HIV-1 Vaccine
David M. Margolis,
University of North Carolina at Chapel Hill, USA
Enlisting Effector Cells to Clear Latent HIV Infection
Enlisting Effector Cells to Clear Latent HIV Infection
Louis J. Picker,
Oregon Health & Science University, USA
CMV-Based HIV Vaccines for HIV Prevention and Clearance
CMV-Based HIV Vaccines for HIV Prevention and Clearance
14:30—16:30
Workshop 2: NHP Models for HIV Vaccines
*
Diane L. Bolton,
US Military HIV Research Program, WRAIR, USA
Nina Rafterman Derby,
Population Council, USA
HSV-2 Infection Increases Rectal SIV?Nef Infection and May Reduce Vaccine Effect
HSV-2 Infection Increases Rectal SIV?Nef Infection and May Reduce Vaccine Effect
Shelby O'Connor,
University of Wisconson-Madison, USA
Tracking SIV Infection and Viral Evolution in vivo using a Barcoded Virus Stock
Tracking SIV Infection and Viral Evolution in vivo using a Barcoded Virus Stock
Hadia Mohammad Abdelaal,
University of Minnesota, USA
CTL-Based Vaccine-Induced Protection is Associated with Induction of High Follicular to Extra-Follicular Ratios of Virus-Specific CD8 T Cells
CTL-Based Vaccine-Induced Protection is Associated with Induction of High Follicular to Extra-Follicular Ratios of Virus-Specific CD8 T Cells
Namal Liyanage,
Ohio State University, College of Medicine, USA
Recruitment of Vaccine Induced MMucosal IL17+NKp44+Innate Lymphoid Cells (ILCs) to Decrease the Risk of SIVmac251 Acquisition in Macaques
Recruitment of Vaccine Induced MMucosal IL17+NKp44+Innate Lymphoid Cells (ILCs) to Decrease the Risk of SIVmac251 Acquisition in Macaques
M. Anthony Moody,
Duke University Medical Center, USA
Vaccine-Induced Anatomic Distribution of Env-Specific B Cell Repertoires: Implications for the Genesis of Induced Mucosal Antibodies in Rhesus Macaques
Vaccine-Induced Anatomic Distribution of Env-Specific B Cell Repertoires: Implications for the Genesis of Induced Mucosal Antibodies in Rhesus Macaques
George M. Shaw,
University of Pennsylvania, USA
Jay A. Berzofsky,
NCI, National Institutes of Health, USA
Immune Activation and the Microbiome in Mucosal Transmission of SHIV
Immune Activation and the Microbiome in Mucosal Transmission of SHIV
Donald Forthal,
University of California, Irvine, USA
Non-Neutralizing Antibodies Reduce the Rate of SIVmac251 Infection Following Low-Dose Repeated Penile Challenge
Non-Neutralizing Antibodies Reduce the Rate of SIVmac251 Infection Following Low-Dose Repeated Penile Challenge
17:00—18:45
Reservoirs and Persistence II
*
Douglas D. Richman,
University of California, San Diego, USA
Sarah E. Palmer,
University of Sydney, Australia
Characterizing the HIV-1 Reservoir During Long-Term Therapy
Characterizing the HIV-1 Reservoir During Long-Term Therapy
Vicente Planelles,
University of Utah, USA
Novel Classes of HIV Latency-Reversing Agents
Novel Classes of HIV Latency-Reversing Agents
Nancie M. Archin,
University of North Carolina at Chapel Hill, USA
Updates on in vivo Administration of Vorinostat
Updates on in vivo Administration of Vorinostat
17:00—18:45
Bridging Innate and Acquired Immunity
This session aims to emphasize the potential importance of non-neutralizing antibodies and their mechanisms.
*
Nicole Frahm,
Bill & Melinda Gates Medical Research Institute, USA
Stylianos Bournazos,
Rockefeller University, USA
Optimizing Antibody-FcR Interactions
Optimizing Antibody-FcR Interactions
George K. Lewis,
University of Maryland, USA
Qualitative and Quantitative Variables that Contribute to Fc-mediated Protection Against HIV-1
Qualitative and Quantitative Variables that Contribute to Fc-mediated Protection Against HIV-1
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
